Trial · NCT03205995
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Platelet Count (10^9 Platelets/L) Change From Baseline at Week 26 | OMS721 (Narsoplimab) | 42 | Full Range -21 to 115.5 | 10^9 platelets/L | |
| Safety as Measured by Incidences of Adverse Events, Vital Signs, ECG, and Clinical Laboratory Tests | OMS721 (Narsoplimab) | 6 | Participants | ||
| Thrombotic Microangiopathies (TMA) Response | OMS721 (Narsoplimab) | 0 | Participants | ||
| TMA Event-free Status | OMS721 (Narsoplimab) | 2 | Participants | ||
| Increase in Estimated Glomerular Filtration Rate (eGFR) | OMS721 (Narsoplimab) | 0 | Participants | ||
| Hematological Normalization | OMS721 (Narsoplimab) | 1 | Participants | ||
| TMA Remission | OMS721 (Narsoplimab) | 2 | Participants | ||
| Incidence of Antidrug Antibodies (ADA) | OMS721 (Narsoplimab) | 1 | Participants | ||
| Change From Baseline in Serum Creatinine (mg/dL) | OMS721 (Narsoplimab) | 1.53 | Full Range -0.98 to 3.16 | mg/dL | |
| Change From Baseline in Serum LDH (U/L) | OMS721 (Narsoplimab) | -12 | Full Range -112 to 389 | U/L | |
| Change From Baseline in Haptoglobin (mg/dL) | OMS721 (Narsoplimab) | 30 | Full Range 4 to 56 | mg/dL | |
| Pharmacokinetics (PK): Trough Plasma Concentration, Lower Limit of Quantification (LLOQ) | OMS721 (Narsoplimab) | 15477.2 | Standard Deviation 6471.62 | ng/mL | |
| Pharmacokinetics (PK): Maximum Plasma Concentrations (Cmax) | OMS721 (Narsoplimab) | 48350 | Full Range 25100 to 86300 | ng/mL | |
| Pharmacodynamics (PD): Inhibition of C3 Activity (%) | OMS721 (Narsoplimab) | 84.4 | Full Range 1.7 to 101.4 | Inhibition of C3 activity (%) | |
| Pharmacodynamics (PD): Inhibition of C4 Activity (%) | OMS721 (Narsoplimab) | 91.9 | Full Range 11.9 to 99.9 | Inhibition of C4 activity (%) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03205995/results